Results 21 to 30 of about 39,159 (175)

Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B

The Turkish Journal of Gastroenterology, 2016
Background/Aims: Several guidelines recommend the use of tenofovir or entecavir as the first-line treatment for hepatitis B due to the lower resistance rates of these drugs than lamivudine, although lamivudine may still be preferred because of its low ...
Kadri Atay, İbrahim Hatemi, Billur Canbakan, Emine Köroğlu, Emre Durcan, Berna Yurttaş, İlhami Gültepe, Sebati Özdemir, Murat Tuncer, Abdullah Sonsuz   +9 more
doaj   +1 more source

Method development and validation for multi-component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-visible spectrophotometer & RP-HPLC

Journal of Applied Pharmaceutical Research, 2020
A novel, simple, precise and accurate method developed for the estimation of Lamivudine and tenofovir disoproxil fumarate (TDF) in bulk drug form has been established. Lamivudine and tenofovir are well known drugs and used in treatment of HIV- Ⅰ.
Shweta Sharma, Amar Deep Ankalgi, Pooja Kaushal, M. S. Ashawat   +3 more
doaj   +1 more source

Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine

BMC Infectious Diseases, 2004
Background Lamivudine inhibits replication of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and is commonly used as part of antiretroviral therapy. The main limitation in the use of lamivudine is resistant mutation selection.
Arabe Juçara, Sucupira Michel VF, Santos Eneida A, Gomes Selma A   +3 more
doaj   +1 more source

Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254] [PDF]

, 2008
Patients with chronic hepatitis B virus (HBV) infection have a substantial risk of reactivation and jaundice following the use of immunosuppressant therapy.
Pol, Stanislas, Hayes, Peter C, Mills, Peter R, Carman, William, Mutimer, David, Barclay, Stephen, Benhamou, Yves, Cameron, Sheila, Pol, S, Barclay, S, Hayes, Patrick, Benhamou, Y, Carman, W, Cameron, S, Mills, P   +14 more
core   +1 more source

PRETREATMENT WITH PEGYLATED INTERFERON PREVENTS EMERGENCE OF LAMIVUDINE MUTANTS IN LAMIVUDINE NAIVE PATIENTS

, 2009
Background: In patients with advanced fibrosis, primary end points of long-term or possibly indefinite antiviral therapy are sustained inhibition of viral replication and avoidance of emergence of resistance. In lamivudine-treated patients, the strongest
CRITELLI R., GRAZIOSI A, LEI B, TALIANI, Gloria, VILLA E   +4 more
core   +2 more sources

Experience with lamivudine treatment for severe acute hepatitis B [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2014
Introduction. Experience with lamivudine treatment for acute severe hepatitis B is limited. Fulminant hepatitis develops in 1% of immunocompetent patients with acute hepatitis B. Objective.
Verhaz Antonija
doaj   +1 more source

LIVER TRANSPLANTATION AND HBV INFECTION

Вестник трансплантологии и искусственных органов, 2009
The paper describes the modern approaches in treatment of hepatitis B virus (HBV)-infected patients who underwent liver transplantation. The patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation (OLT) have to receive long ...
O. I. Andreytseva, A. V. Kozlova, V. E. Sutkin   +2 more
doaj   +1 more source

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. [PDF]

, 2012
BACKGROUND: The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy.
Alec Miners, Valentina Cambiano (146513), von Wyl Viktor, Phillips, Andrew N, Andrew N Phillips, Jens Lundgren, Valentina Cambiano, Silvia Bertagnolio, Pillay Deenan, Pillay, Deenan, Deenan Pillay (7888), Bertagnolio, Silvia, Miners Alec, Michael R. Jordan (146520), Cambiano, Valentina, von Wyl, Viktor, Viktor von Wyl, Phillips Andrew N., Jordan, Michael R, Cambiano Valentina, Miners, Alec, Bertagnolio Silvia, Lundgren Jens, Andrew N. Phillips (146556), Lundgren, Jens, Alec Miners (146534), Viktor von Wyl (146506), Silvia Bertagnolio (57174), Michael R Jordan, Deenan Pillay, Jens Lundgren (146550), Jordan Michael R.   +31 more
core   +2 more sources

THE STUDY OF INFLUENCE OF PREPARATION «COMBIVIR» ON CARBOHYDRATE AND LIPID METABOLISM OF BLOOD SERUM

Современная наука и инновации, 2022
The purpose of this study was to evaluate the effect of the drug «Combivir» on indicators of carbohydrate metabolism and serum lipids in the systemic toxicity study conducted in conditions of chronic experiment.
Elena Olegovna Sergeeva, Lubov Anatolievna Sadjaya, Alexander Yurievich Terekhov   +2 more
doaj  

Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting

HIV Research & Clinical Practice, 2022
Objectives: To evaluate the impact of a treatment switch to dolutegravir plus lamivudine on the soluble inflammatory biomarkers of HIV-infected patients treated in a real-life setting.
Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto   +7 more
doaj   +1 more source